• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.

作者信息

Eleftheriadou Aikaterini, Riley David, Zhao Sizheng S, Austin Philip, Hernández Gema, Lip Gregory Y H, Jackson Timothy L, Wilding John P H, Alam Uazman

机构信息

Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.

Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

出版信息

Diabetologia. 2025 Jan;68(1):249-250. doi: 10.1007/s00125-024-06314-1. Epub 2024 Nov 7.

DOI:10.1007/s00125-024-06314-1
PMID:39505765
Abstract
摘要

相似文献

1
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.解决评估SGLT2抑制剂和GLP-1受体激动剂对糖尿病眼部并发症影响中的方法学考量。对Tsai Y-H、Hemphill NO、Kurth T的回复
Diabetologia. 2025 Jan;68(1):249-250. doi: 10.1007/s00125-024-06314-1. Epub 2024 Nov 7.
2
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications.探讨评估钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂对糖尿病眼部并发症风险影响时的方法学考量。
Diabetologia. 2025 Jan;68(1):247-248. doi: 10.1007/s00125-024-06300-7. Epub 2024 Oct 30.
3
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.在台湾，衰弱对 2 型糖尿病患者 GLP-1 受体激动剂与 SGLT2 抑制剂有效性和安全性的影响：一项回顾性、全国性、纵向研究。
Lancet Healthy Longev. 2024 Sep;5(9):100621. doi: 10.1016/j.lanhl.2024.07.004. Epub 2024 Sep 13.
4
SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review.SGLT2抑制剂、GLP-1激动剂和DPP-4抑制剂在糖尿病及微血管并发症中的应用：综述
Int J Endocrinol. 2020 Feb 29;2020:1762164. doi: 10.1155/2020/1762164. eCollection 2020.
5
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.SGLT2 抑制剂、GLP-1 受体激动剂、DPP-4 抑制剂和磺脲类药物对主要不良心血管事件风险的比较效果：使用电子健康记录模拟随机目标试验。
Lancet Diabetes Endocrinol. 2023 Sep;11(9):644-656. doi: 10.1016/S2213-8587(23)00171-7. Epub 2023 Jul 24.
6
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.GLP-1 受体激动剂单药及与 SGLT2 抑制剂联合治疗 2 型糖尿病的心血管、肾脏和安全性结局：系统评价和荟萃分析。
Circulation. 2024 Nov 26;150(22):1781-1790. doi: 10.1161/CIRCULATIONAHA.124.071689. Epub 2024 Aug 30.
7
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.2型糖尿病治疗效果的年龄和性别差异：一项网状Meta分析
JAMA. 2025 Mar 25;333(12):1062-1073. doi: 10.1001/jama.2024.27402.
8
Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.在全国2型糖尿病患者群体中，GLP-1受体激动剂和SGLT2抑制剂使用者的治疗中断情况。
Diabetologia. 2025 May 2. doi: 10.1007/s00125-025-06439-x.
9
Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂在预防2型糖尿病患者患阿尔茨海默病、血管性痴呆及其他类型痴呆方面的比较疗效。
Diabetes Metab. 2025 Mar;51(2):101623. doi: 10.1016/j.diabet.2025.101623. Epub 2025 Feb 12.
10
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.扩大低收入和中等收入国家2型糖尿病患者获得新型药物的机会：成本效益和价格目标分析
Lancet Diabetes Endocrinol. 2021 Dec;9(12):825-836. doi: 10.1016/S2213-8587(21)00240-0. Epub 2021 Oct 14.

本文引用的文献

1
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications.探讨评估钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂对糖尿病眼部并发症风险影响时的方法学考量。
Diabetologia. 2025 Jan;68(1):247-248. doi: 10.1007/s00125-024-06300-7. Epub 2024 Oct 30.
2
Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.胰高血糖素样肽 1 受体激动剂的使用与甲状腺癌风险：斯堪的纳维亚队列研究。
BMJ. 2024 Apr 10;385:e078225. doi: 10.1136/bmj-2023-078225.
3
Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽 1 受体激动剂治疗 2 型糖尿病的糖尿病视网膜病变和糖尿病黄斑水肿风险：来自全球联合数据库的真实世界数据研究。
Diabetologia. 2024 Jul;67(7):1271-1282. doi: 10.1007/s00125-024-06132-5. Epub 2024 Apr 8.
4
The Detection of Date Shifting in Real-World Data.真实世界数据中的日期错位检测。
Appl Clin Inform. 2023 Aug;14(4):763-771. doi: 10.1055/a-2130-2197. Epub 2023 Jul 17.
5
Automatic Outlier Detection in Laboratory Result Distributions Within a Real World Data Network.在真实世界数据网络中检测实验室结果分布中的自动异常值。
Stud Health Technol Inform. 2023 May 18;302:88-92. doi: 10.3233/SHTI230070.
6
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.使用钠-葡萄糖协同转运蛋白2抑制剂治疗的2型糖尿病患者的泌尿道和生殖器感染：一项随机对照试验的荟萃分析
Diabetes Obes Metab. 2017 Mar;19(3):348-355. doi: 10.1111/dom.12825. Epub 2016 Dec 19.